Superficial AdenopathyEGASNCT02645825
Predictive Character Analysis of Ganglionic Echography for the Diagnostic of Benin or Malignant Superficial Adenopathy
An observational study of Superficial Adenopathy, run by University Hospital, Brest.
Trial summary
Investigators need to establish a formal diagnostic of superficial adenopathy through complementary investigations to find etiologic diagnostic ( Echography, adenogram). Echography examination should be a guide to take in charge the adenopathy and to predict presence of malignant (primitive) or benin (reactional)… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Superficial Adenopathy
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- May 2016to Apr 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient from ambulatory medicine consultation with superficial adenopathy
Who may be able to join
- superficial adenopathy
Who cannot join
- obvious adenopathy
About this study
Official title: Analyse du caractère prédictif de l'échographie Ganglionnaire Pour le Diagnostic de bégninité ou malignité d'Une adénopathie Superficielle
Investigators need to establish a formal diagnostic of superficial adenopathy through complementary investigations to find etiologic diagnostic ( Echography, adenogram).
Echography examination should be a guide to take in charge the adenopathy and to predict presence of malignant (primitive) or benin (reactional) character of adenopathy. The aim of this study is to codify the management of adenopathic patient with a diagnostic in 48 hours after examination. This fast diagnostic helps to prevent unnecessary biopsy, to avoid wasting time in case of a serious pathology.
- Conditions
- Superficial Adenopathy
- Keywords
- superficial adenopathy - echography
What is being measured
The primary outcome is the main question the study is designed to answer.
Parameter of echography
The benign or malignant nature of adenopathy (or lymphadenopathy) confirmed by adenogram results +/- lymph node biopsy (as the gold standard)"
Measured: inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2016 (estimated)
- Study startMay 2016
- Primary completionApr 2019 (estimated)
- Study completionApr 2019 (estimated)
Why it stopped: Expected prevalence rates are not objective The number of patients that can be included is much lower than expected The protocol is too complicated for primary care The questionnaires are too long
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Superficial AdenopathyStudies of the same condition, open and under way.
- More trials run by University Hospital, BrestThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Christian Berthou, Principal investigator, CHRU de Brest
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02645825
- Sponsor's protocol ID
- EGAS - RB 14.077
- Acronym
- EGAS
- Status last verified
- Jun 2026
- First submitted
- 4 Jan 2016
- Last updated
- 26 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analyse du caractère prédictif de l'échographie Ganglionnaire Pour le Diagnostic de bégninité ou malignité d'Une adénopathie Superficielle
- ClinicalTrials.gov ID
- NCT02645825
- Acronym / sponsor ID
- EGAS / EGAS - RB 14.077
- Conditions
- Superficial Adenopathy
- Keywords
- superficial adenopathy - echography
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Expected prevalence rates are not objective The number of patients that can be included is much lower than expected The protocol is too complicated for primary care The questionnaires are too long
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- May 2016
- Primary completion
- Apr 2019 (estimated)
- Study completion
- Apr 2019 (estimated)
- First posted
- 5 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigators need to establish a formal diagnostic of superficial adenopathy through complementary investigations to find etiologic diagnostic ( Echography, adenogram).
Echography examination should be a guide to take in charge the adenopathy and to predict presence of malignant (primitive) or benin (reactional) character of adenopathy. The aim of this study is to codify the management of adenopathic patient with a diagnostic in 48 hours after examination. This fast diagnostic helps to prevent unnecessary biopsy, to avoid wasting time in case of a serious pathology.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient from ambulatory medicine consultation with superficial adenopathy
Key inclusion criteria (1 listed)
- superficial adenopathy
Key exclusion criteria (1 listed)
- obvious adenopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Parameter of echography
Time frame: inclusion
The benign or malignant nature of adenopathy (or lymphadenopathy) confirmed by adenogram results +/- lymph node biopsy (as the gold standard)"
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
Related trials for Superficial Adenopathy
RecruitingObservational study
Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
Lymphadenopathy, Lymphnode Metastasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian Berthou principal investigator
CHRU de Brest
Questions about this trial
What is this clinical trial studying?
An observational study of Superficial Adenopathy, run by University Hospital, Brest.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Parameter of echography (time frame: inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.